|
1
|
Vagia E, Mahalingam D and Cristofanilli M:
The landscape of targeted therapies in TNBC. Cancers (Basel).
12(916)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jiang MJ, Chen YY, Dai JJ, Gu DN, Mei Z,
Liu FR, Huang Q and Tian L: Dying tumor cell-derived exosomal
miR-194-5p potentiates survival and repopulation of tumor
repopulating cells upon radiotherapy in pancreatic cancer. Mol
Cancer. 19(68)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang Y, Zhao M, He S, Luo Y, Zhao Y, Cheng
J, Gong Y, Xie J, Wang Y, Hu B, et al: Necroptosis regulates tumor
repopulation after radiotherapy via RIP1/RIP3/MLKL/JNK/IL8 pathway.
J Exp Clin Cancer Res. 38(461)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Candas-Green D, Xie B, Huang J, Fan M,
Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, et al: Dual
blockade of CD47 and HER2 eliminates radioresistant breast cancer
cells. Nat Commun. 11(4591)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bai X, Ni J, Beretov J, Wang S, Dong X,
Graham P and Li Y: THOC2 and THOC5 regulate stemness and
radioresistance in triple-negative breast cancer. Adv Sci (Weinh).
8(e2102658)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Colli LM, Machiela MJ, Zhang H, Myers TA,
Jessop L, Delattre O, Yu K and Chanock SJ: Landscape of combination
immunotherapy and targeted therapy to improve cancer management.
Cancer Res. 77:3666–3671. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Seebacher NA, Stacy AE, Porter GM and
Merlot AM: Clinical development of targeted and immune based
anti-cancer therapies. J Exp Clin Cancer Res.
38(156)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Trenker R and Jura N: Receptor tyrosine
kinase activation: From the ligand perspective. Curr Opin Cell
Biol. 63:174–185. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Colavito SA: AXL as a target in breast
cancer therapy. J Oncol. 2020(5291952)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Aguilera TA, Rafat M, Castellini L,
Shehade H, Kariolis MS, Hui AB, Stehr H, von Eyben R, Jiang D,
Ellies LG, et al: Reprogramming the immunological microenvironment
through radiation and targeting Axl. Nat Commun.
7(13898)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tang Y, Zang H, Wen Q and Fan S: AXL in
cancer: A modulator of drug resistance and therapeutic target. J
Exp Clin Cancer Res. 42(148)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li H, Liu Z, Liu L, Zhang H, Han C, Girard
L, Park H, Zhang A, Dong C, Ye J, et al: AXL targeting restores
PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through
expansion of TCF1(+) CD8 T cells. Cell Rep Med.
3(100554)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Noronha A, Nataraj NB, Lee JS, Zhitomirsky
B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, et al:
AXL and error-prone DNA replication confer drug resistance and
offer strategies to treat EGFR-mutant lung cancer. Cancer Discov.
12:2666–2683. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
He R, Song Z, Bai Y, He S, Huang J, Wang
Y, Zhou F, Huang W, Guo J, Wang Z, et al: Discovery of AXL
degraders with improved potencies in triple-negative breast cancer
(TNBC) cells. J Med Chem. 66:1873–1891. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bottai G, Raschioni C, Székely B, Di
Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R,
Karachaliou N, et al: AXL-associated tumor inflammation as a poor
prognostic signature in chemotherapy-treated triple-negative breast
cancer patients. NPJ Breast Cancer. 2(16033)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Han J, Tian R, Yong B, Luo C, Tan P, Shen
J and Peng T: Gas6/Axl mediates tumor cell apoptosis, migration and
invasion and predicts the clinical outcome of osteosarcoma
patients. Biochem Biophys Res Commun. 435:493–500. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhu C, Wei Y and Wei X: AXL receptor
tyrosine kinase as a promising anti-cancer approach: Functions,
molecular mechanisms and clinical applications. Mol Cancer.
18(153)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tai KY, Shieh YS, Lee CS, Shiah SG and Wu
CW: Axl promotes cell invasion by inducing MMP-9 activity through
activation of NF-kappaB and Brg-1. Oncogene. 27:4044–4055.
2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:7570–7579. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Miricescu D, Totan A, Stanescu-Spinu II,
Badoiu SC, Stefani C and Greabu M: PI3K/AKT/mTOR signaling pathway
in breast cancer: From molecular landscape to clinical aspects. Int
J Mol Sci. 22(173)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Park JH, Kim YH, Shim S, Kim A, Jang H,
Lee SJ, Park S, Seo S, Jang WI, Lee SB and Kim MJ:
Radiation-activated PI3K/AKT pathway promotes the induction of
cancer stem-like cells via the upregulation of SOX2 in colorectal
cancer. Cells. 10(135)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Seol MY, Choi SH and Yoon HI: Combining
radiation with PI3K isoform-selective inhibitor administration
increases radiosensitivity and suppresses tumor growth in non-small
cell lung cancer. J Radiat Res. 63:591–601. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yu L, Guo Q, Luo Z, Wang Y, Weng J, Chen
Y, Liang W, Li Y, Zhang Y, Chen K, et al: TXN inhibitor impedes
radioresistance of colorectal cancer cells with decreased ALDH1L2
expression via TXN/NF-κB signaling pathway. Br J Cancer.
127:637–648. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Spring E and Holmberg P: Evaluation of
experimental irradiation fractionation with the single-hit,
multi-target model. Acta Radiol Ther Phys Biol. 7:297–306.
1968.PubMed/NCBI View Article : Google Scholar
|
|
26
|
du Sert NP, Ahluwalia A, Alam S, Avey MT,
Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, et
al: Reporting animal research: Explanation and elaboration for the
ARRIVE guidelines 2.0. PLoS Biol. 18(e3000411)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Butti R, Das S, Gunasekaran VP, Yadav AS,
Kumar D and Kundu GC: Receptor tyrosine kinases (RTKs) in breast
cancer: Signaling, therapeutic implications and challenges. Mol
Cancer. 17(34)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Itoh T, Hatano R, Horimoto Y, Yamada T,
Song D, Otsuka H, Shirakawa Y, Mastuoka S, Iwao N, Aune TM, et al:
IL-26 mediates epidermal growth factor receptor-tyrosine kinase
inhibitor resistance through endoplasmic reticulum stress signaling
pathway in triple-negative breast cancer cells. Cell Death Dis.
12(520)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang S, Xu XS, Yang JX, Guo JH, Chao TF
and Tong Y: The prognostic role of Gas6/Axl axis in solid
malignancies: A meta-analysis and literature review. Onco Targets
Ther. 11:509–519. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tanaka K, Tokunaga E, Inoue Y, Yamashita
N, Saeki H, Okano S, Kitao H, Oki E, Oda Y and Maehara Y: Impact of
expression of vimentin and Axl in breast cancer. Clin Breast
Cancer. 16:520–526. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:1124–1129.
2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zajac O, Leclere R, Nicolas A, Meseure D,
Marchiò C, Vincent-Salomon A, Roman-Roman S, Schoumacher M and
Dubois T: AXL controls directed migration of mesenchymal
triple-negative breast cancer cells. Cells. 9(247)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Leconet W, Chentouf M, du Manoir S,
Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M,
Radosevic-Robin N, Theillet C, et al: Therapeutic activity of
Anti-AXL antibody against triple-negative breast cancer
patient-derived xenografts and metastasis. Clin Cancer Res.
23:2806–2816. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Abdel-Rahman WM, Al-Khayyal NA, Nair VA,
Aravind SR and Saber-Ayad M: Role of AXL in invasion and drug
resistance of colon and breast cancer cells and its association
with p53 alterations. World J Gastroenterol. 23:3440–3448.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Holland SJ, Powell MJ, Franci C, Chan EW,
Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, et
al: Multiple roles for the receptor tyrosine kinase axl in tumor
formation. Cancer Res. 65:9294–9303. 2005.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jiang C, Cheng Z, Jiang T, Xu Y and Wang
B: MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal
transition via targeting AXL/PI3K/AKT/Snail signaling in
nasopharyngeal carcinoma. Genes Genomics. 42:971–978.
2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Corno C, Gatti L, Lanzi C, Zaffaroni N,
Colombo D and Perego P: Role of the receptor tyrosine kinase axl
and its targeting in cancer cells. Curr Med Chem. 23:1496–1512.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Aoki M and Fujishita T: Oncogenic roles of
the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY,
Kim CH, Park HG, Han SI and Kang HS: Induction of metastasis,
cancer stem cell phenotype, and oncogenic metabolism in cancer
cells by ionizing radiation. Mol Cancer. 16(10)2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yuan Y, Liao H, Pu Q, Ke X, Hu X, Ma Y,
Luo X, Jiang Q, Gong Y, Wu M, et al: miR-410 induces both
epithelial-mesenchymal transition and radioresistance through
activation of the PI3K/mTOR pathway in non-small cell lung cancer.
Signal Transduct Target Ther. 5(85)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Leiker AJ, DeGraff W, Choudhuri R, Sowers
AL, Thetford A, Cook JA, Van Waes C and Mitchell JB: Radiation
enhancement of head and neck squamous cell carcinoma by the dual
PI3K/mTOR inhibitor PF-05212384. Clin Cancer Res. 21:2792–2801.
2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Albert JM, Kim KW, Cao C and Lu B:
Targeting the Akt/mammalian target of rapamycin pathway for
radiosensitization of breast cancer. Mol Cancer Ther. 5:1183–1189.
2006.PubMed/NCBI View Article : Google Scholar
|
